Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
Clinical trial NCT05738434 · RECRUITING
Trial details
- NCT number
- NCT05738434
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-02
- Primary completion
- 2025-09-01
- Enrollment
- 188
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.